vs
Side-by-side financial comparison of Claritev Corp (CTEV) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $123.8M, roughly 2.0× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -32.7%, a 36.0% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs 4.7%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 2.5%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
CTEV vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $123.8M |
| Net Profit | $-80.6M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | -3.1% | 4.3% |
| Net Margin | -32.7% | 3.3% |
| Revenue YoY | 6.2% | 4.7% |
| Net Profit YoY | 41.6% | 1379.4% |
| EPS (diluted) | $-4.88 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $123.8M | ||
| Q3 25 | $246.0M | $128.3M | ||
| Q2 25 | $241.6M | $114.8M | ||
| Q1 25 | $231.3M | $113.2M | ||
| Q4 24 | $232.1M | $118.2M | ||
| Q3 24 | $230.5M | $114.6M | ||
| Q2 24 | $233.5M | $110.6M | ||
| Q1 24 | $234.5M | $111.0M |
| Q4 25 | $-80.6M | $4.1M | ||
| Q3 25 | $-69.8M | $5.3M | ||
| Q2 25 | $-62.6M | $5.3M | ||
| Q1 25 | $-71.3M | $4.7M | ||
| Q4 24 | $-138.0M | $-321.0K | ||
| Q3 24 | $-391.4M | $4.3M | ||
| Q2 24 | $-576.7M | $1.3M | ||
| Q1 24 | $-539.7M | $2.3M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% | ||
| Q1 24 | — | 71.2% |
| Q4 25 | -3.1% | 4.3% | ||
| Q3 25 | 4.1% | 7.0% | ||
| Q2 25 | 6.9% | 3.7% | ||
| Q1 25 | 4.2% | 5.4% | ||
| Q4 24 | -17.8% | 3.8% | ||
| Q3 24 | -146.7% | 4.6% | ||
| Q2 24 | -224.4% | 5.1% | ||
| Q1 24 | -207.4% | 4.2% |
| Q4 25 | -32.7% | 3.3% | ||
| Q3 25 | -28.4% | 4.2% | ||
| Q2 25 | -25.9% | 4.6% | ||
| Q1 25 | -30.8% | 4.2% | ||
| Q4 24 | -59.4% | -0.3% | ||
| Q3 24 | -169.8% | 3.8% | ||
| Q2 24 | -247.0% | 1.2% | ||
| Q1 24 | -230.1% | 2.1% |
| Q4 25 | $-4.88 | $0.23 | ||
| Q3 25 | $-4.23 | $0.30 | ||
| Q2 25 | $-3.81 | $0.28 | ||
| Q1 25 | $-4.38 | $0.25 | ||
| Q4 24 | $-8.49 | $-0.02 | ||
| Q3 24 | $-24.25 | $0.23 | ||
| Q2 24 | $-35.78 | $0.07 | ||
| Q1 24 | $-33.40 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $93.9M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $161.6M |
| Total Assets | $4.9B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $93.9M | ||
| Q3 25 | $39.2M | $95.6M | ||
| Q2 25 | $56.4M | $81.3M | ||
| Q1 25 | $23.1M | $86.5M | ||
| Q4 24 | $16.8M | $84.7M | ||
| Q3 24 | $86.6M | $78.7M | ||
| Q2 24 | $48.8M | $68.7M | ||
| Q1 24 | $58.7M | $77.8M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | $2.1M |
| Q4 25 | $-173.9M | $161.6M | ||
| Q3 25 | $-101.8M | $166.7M | ||
| Q2 25 | $-39.9M | $163.7M | ||
| Q1 25 | $14.8M | $167.1M | ||
| Q4 24 | $84.0M | $161.0M | ||
| Q3 24 | $207.6M | $162.6M | ||
| Q2 24 | $603.4M | $156.4M | ||
| Q1 24 | $1.2B | $159.7M |
| Q4 25 | $4.9B | $261.1M | ||
| Q3 25 | $5.0B | $264.8M | ||
| Q2 25 | $5.1B | $254.9M | ||
| Q1 25 | $5.1B | $252.7M | ||
| Q4 24 | $5.2B | $240.9M | ||
| Q3 24 | $5.3B | $245.3M | ||
| Q2 24 | $5.7B | $235.8M | ||
| Q1 24 | $6.4B | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $9.9M |
| Free Cash FlowOCF − Capex | $36.4M | $7.6M |
| FCF MarginFCF / Revenue | 14.8% | 6.1% |
| Capex IntensityCapex / Revenue | 12.1% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $9.9M | ||
| Q3 25 | $19.9M | $18.5M | ||
| Q2 25 | $61.2M | $4.3M | ||
| Q1 25 | $-30.1M | $2.6M | ||
| Q4 24 | $-33.4M | $12.2M | ||
| Q3 24 | $72.8M | $9.6M | ||
| Q2 24 | $18.5M | $1.3M | ||
| Q1 24 | $49.7M | $2.2M |
| Q4 25 | $36.4M | $7.6M | ||
| Q3 25 | $-16.3M | $16.8M | ||
| Q2 25 | $36.6M | $3.0M | ||
| Q1 25 | $-68.9M | $1.5M | ||
| Q4 24 | $-63.8M | $10.0M | ||
| Q3 24 | $41.1M | $7.9M | ||
| Q2 24 | $-7.0M | $-2.0M | ||
| Q1 24 | $19.2M | $-1.5M |
| Q4 25 | 14.8% | 6.1% | ||
| Q3 25 | -6.6% | 13.1% | ||
| Q2 25 | 15.2% | 2.6% | ||
| Q1 25 | -29.8% | 1.3% | ||
| Q4 24 | -27.5% | 8.5% | ||
| Q3 24 | 17.8% | 6.9% | ||
| Q2 24 | -3.0% | -1.9% | ||
| Q1 24 | 8.2% | -1.4% |
| Q4 25 | 12.1% | 1.9% | ||
| Q3 25 | 14.7% | 1.3% | ||
| Q2 25 | 10.2% | 1.2% | ||
| Q1 25 | 16.8% | 1.0% | ||
| Q4 24 | 13.1% | 1.9% | ||
| Q3 24 | 13.8% | 1.5% | ||
| Q2 24 | 10.9% | 3.0% | ||
| Q1 24 | 13.0% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
